KORU Medical Systems Inc

KORU Medical Systems Inc (KRMD) Stock Analysis

$3.030

-0.222 (-7.34%)At close

Loading chart…
High
3.310
Open
3.310
VWAP
3.09
Volume
143.77K
Mkt Cap
130.43M
Low
2.920
Amount
443.78K
EV/EBITDA, TTM
36.88

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

AI analysis of KORU Medical Systems Inc (KRMD)

Buy

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

Valuation Metrics

The current forward P/E ratio for KORU Medical Systems Inc (KRMD) is 76.34, compared to its 5-year average forward P/E of -7.42.

Forward P/E

Fair
5Y Average P/E
-7.42
Current P/E
76.34
Overvalued
108.26
Undervalued
-123.09

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-24.07
Current EV/EBITDA
36.88
Overvalued
59.60
Undervalued
-107.75

Forward P/S

Undervalued
5Y Average P/S
4.07
Current P/S
2.53
Overvalued
5.09
Undervalued
3.05

Alphio AI Price Scenarios for KRMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%KRMD

$3.23

Scenario price

B

Base

Base · 50%KRMD

$2.98

Scenario price

B

Bear

Bear · 25%KRMD

$2.84

Scenario price

Whales holding KRMD

F

First Light Asset Management, LLC

+ HoldingKRMD

+0.00%

3M Return

Events Timeline

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

KORU Medical Reports Q4 Revenue of $10.9M

News

KRMD FAQ — answered by Alphio AI

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading